Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41


The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal.

Brezing CA, Levin FR.

Neuropsychopharmacology. 2018 Jan;43(1):173-194. doi: 10.1038/npp.2017.212. Epub 2017 Sep 6. Review.


Smoked marijuana attenuates performance and mood disruptions during simulated night shift work.

Keith DR, Gunderson EW, Haney M, Foltin RW, Hart CL.

Drug Alcohol Depend. 2017 Sep 1;178:534-543. doi: 10.1016/j.drugalcdep.2017.04.036. Epub 2017 Jun 28.


Evidence-based Treatment Options in Cannabis Dependency.

Walther L, Gantner A, Heinz A, Majić T.

Dtsch Arztebl Int. 2016 Sep 30;113(39):653-659. doi: 10.3238/arztebl.2016.0653. Review.


Progress toward pharmacotherapies for cannabis-use disorder: an evidence-based review.

Copeland J, Pokorski I.

Subst Abuse Rehabil. 2016 May 3;7:41-53. doi: 10.2147/SAR.S89857. eCollection 2016. Review.


Sleep abnormalities associated with alcohol, cannabis, cocaine, and opiate use: a comprehensive review.

Angarita GA, Emadi N, Hodges S, Morgan PT.

Addict Sci Clin Pract. 2016 Apr 26;11(1):9. doi: 10.1186/s13722-016-0056-7. Review.


Treatment of Cannabis Use Disorder: Current Science and Future Outlook.

Sherman BJ, McRae-Clark AL.

Pharmacotherapy. 2016 May;36(5):511-35. doi: 10.1002/phar.1747. Review.


Outcomes from a computer-assisted intervention simultaneously targeting cannabis and tobacco use.

Lee DC, Budney AJ, Brunette MF, Hughes JR, Etter JF, Stanger C.

Drug Alcohol Depend. 2015 Oct 1;155:134-40. doi: 10.1016/j.drugalcdep.2015.08.001. Epub 2015 Aug 10.


Cannabis and psychopathology: The meandering journey of the last decade.

Ghosh A, Basu D.

Indian J Psychiatry. 2015 Apr-Jun;57(2):140-9. doi: 10.4103/0019-5545.158134. Review.


Pharmacotherapies for cannabis dependence.

Marshall K, Gowing L, Ali R, Le Foll B.

Cochrane Database Syst Rev. 2014;(12):CD008940. doi: 10.1002/14651858.CD008940.pub2. Epub 2014 Dec 17. Review.


Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR?

Kelly MA, Pavlicova M, Glass A, Mariani JJ, Bisaga A, Sullivan MA, Nunes EV, Levin FR.

Drug Alcohol Depend. 2014 Nov 1;144:42-6. doi: 10.1016/j.drugalcdep.2014.06.040. Epub 2014 Jul 11.


MDMA: a social drug in a social context.

Kirkpatrick MG, de Wit H.

Psychopharmacology (Berl). 2015 Mar;232(6):1155-63. doi: 10.1007/s00213-014-3752-6. Epub 2014 Oct 5.


Treatment models for targeting tobacco use during treatment for cannabis use disorder: case series.

Lee DC, Budney AJ, Brunette MF, Hughes JR, Etter JF, Stanger C.

Addict Behav. 2014 Aug;39(8):1224-30. doi: 10.1016/j.addbeh.2014.04.010. Epub 2014 Apr 13.


Neurocognition in college-aged daily marijuana users.

Becker MP, Collins PF, Luciana M.

J Clin Exp Neuropsychol. 2014;36(4):379-98. doi: 10.1080/13803395.2014.893996. Epub 2014 Mar 12.


Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial.

Morley KC, Haber PS, Morgan ML, Samara F.

Subst Abuse Rehabil. 2012 May 28;3:43-7. doi: 10.2147/SAR.S30052. eCollection 2012.


Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.

Verrico CD, Haile CN, Newton TF, Kosten TR, De La Garza R 2nd.

Expert Opin Investig Drugs. 2013 Dec;22(12):1549-68. doi: 10.1517/13543784.2013.836488. Epub 2013 Sep 14. Review. Erratum in: Expert Opin Investig Drugs. 2014 Jun;23(6):885. De La Garza, Richard [corrected to De La Garza, Richard 2nd].


Development of an integrative cessation program for co-smokers of cigarettes and cannabis: demand analysis, program description, and acceptability.

Becker J, Hungerbuehler I, Berg O, Szamrovicz M, Haubensack A, Kormann A, Schaub MP.

Subst Abuse Treat Prev Policy. 2013 Sep 12;8:33. doi: 10.1186/1747-597X-8-33.


In the company of others: social factors alter acute alcohol effects.

Kirkpatrick MG, de Wit H.

Psychopharmacology (Berl). 2013 Nov;230(2):215-26. doi: 10.1007/s00213-013-3147-0. Epub 2013 May 28.


Marijuana dependence: not just smoke and mirrors.

Ramesh D, Schlosburg JE, Wiebelhaus JM, Lichtman AH.

ILAR J. 2011;52(3):295-308. doi: 10.1093/ilar.52.3.295. Review.


A randomized double-blind, placebo-controlled trial of venlafaxine-extended release for co-occurring cannabis dependence and depressive disorders.

Levin FR, Mariani J, Brooks DJ, Pavlicova M, Nunes EV, Agosti V, Bisaga A, Sullivan MA, Carpenter KM.

Addiction. 2013 Jun;108(6):1084-94. doi: 10.1111/add.12108. Epub 2013 Mar 21.

Supplemental Content

Support Center